Monday, January 6, 2025

Soho House & Co: Go-Private Transaction

Another one shared by a reader and similar to 23andMe, Soho House (SHCO)(~$1.5B market cap) is a 2021 vintage IPO that failed to live up to lofty expectations and now after receiving some bad press and investor skepticism, management along with an unnamed consortium want to take it private.  Seems to be a mini-trend (MAPS is another one that was shared).

Soho House is a private social club that was founded in 1995 in London by Nick Jones (he still owns 5.2% of the company, presumably part of the go-private transaction), it now has 45 social clubs around the world, their growth strategy is to target opening 2-4 houses per year.  The clubs (~$4800/year dues) have a fashionable bend to them, cater to younger creative types rather than a stodgy country club crowd, many of the clubs have rooftop pools, gyms, bars, other amenities that young professionals enjoy.  The company has expanded to some ancillary business lines like beach resorts and even furniture sales.  Soho House counts around 200+k full members with another 100+k on the waiting list.  But this business does have its negatives, its hard and costly (heavy maintenance capex business) to keep up an exclusive luxury image and goes counter to the grow story that was pitched during the IPO.

Back in 2012, billionaire media/consumer investor Ron Burkle bought a majority stake in the company via his Yucaipa private-equity vehicle.  After taking the company public, Burkle remains the Chairman of the Board and owns ~47% of the stock, plus more of the vote due to super-voting Class B shares (the publicly traded stock is Class A).  Burkle is a pretty eccentric guy, he reportedly has ties to some Hollywood scandals, bought Michael Jackson's Neverland Ranch and Bob Hope's Palm Springs house, also owns a minority stake in the Pittsburgh Penguins among other private investments.  Soho House likely has some vanity and/or social identity appeal for Burkle; it must be fun to be the owner of Soho House and socialize with their celebrity clientele.

Last February, the company came under fire when GlassHouse Research published a short report with a target price of $0.  The primary arguments were persistent unprofitability, broken growth story, aggressive depreciation schedules and rising debt levels.  Following the report, the company put out a press release announcing they previously had formed a special committee to "evaluate certain strategic transactions, some of which may result in the Company becoming a private company."  Then a couple weeks after (3/18/24), Ron Burkle published an open letter to shareholders:

Dear Shareholders

This is my first note to shareholders since we bought control of the company over a decade ago.

With all that’s gone on recently and my understanding that there has been leaked confidential information from the special committee process, I thought I’d proactively share my thoughts with you directly in the event confidential information is indeed leaked.

I’ve made hundreds of investments in my life, but none with a business model I like better than Soho House. It’s hard to read that we aren’t profitable when our Houses are very profitable and create tremendous long-term value as an in-place network. I feel the real focus should be on mature Houses that are in their second 5-year period of their growth curve, when the profitability and durability of the units really kicks into gear. With approximately half our Houses still less than five years old, we have substantial embedded value that will grow as those Houses mature, even before adding a single new House. Our post five-year Houses contribute on average 35% plus House-Level margin, with some of our oldest Houses well above that, making the network more valuable with time. This a unique and really compelling feature of the business model.

Public companies always have a tug of war over short term vs. long term profits. I’d again emphasize that this (to me) should be about value creation more than anything. Today Soho House is a public company. The Board and its affiliates alone controls approximately 75% of the stock, there aren’t many shares in the public’s hands. We have bought back so much of the small float that at today’s stock price the company can almost go private without any of us writing a check.

When we went public I believed the market would reward growth, but it seemed to quickly switch to rewarding free cash flow and profit over our top-line growth. So at this point in time we have all the costs of being a public company with few benefits. The recent negative write up caused the company to have an outside audit firm be hired by an independent law firm. It’s expensive to be a public company, this year it will be even more for a forensic audit that confirmed there are absolutely no issues and took critical management time away from the business.

...

There has always been a lot of investor interest in Soho House, and now is no exception. It is one-of-a-kind. It’s not a hotel company and it’s not a food and beverage company. It’s a membership company with a lot of demand and very low attrition (which provides a large and growing base of recurring revenues in the multiple hundreds of millions).

The public market doesn’t seem to understand or fully appreciate the value of Soho House, and the interest from the special committee process has shown private buyers may be willing to step-up and close the gap. However, it’s not for me to opine on the fairness or the appropriate value of the company’s stock, especially if I am not intending to be a seller.

In closing, given the mere potential of leaked information involving the special committee process, I wanted to go the extra step to share with you directly how I see the Company, any proposal and the process.

Sincerely,

Ron Burkle 

Despite the usual complaints about being public and the strategic process, Soho House announced in May, it was unable to come to agreement with the third party despite the offer "reflecting a substantial premium over the current trading price".  The special committee was dissolved, process over.  

However, six months later in December, alongside a delayed Q3 earnings (to make things even more murky, this company has some accounting / controls issues) announced that a new third-party consortium offered $9/share and importantly, had the support of Burkle and his affiliates to roll their equity interest into the go-private transaction.

The offer, which is supported by Ron Burkle and Yucaipa, was the result of a thorough strategic review undertaken by Yucaipa and its financial advisors to enhance shareholder value, as Yucaipa believes the inherent value of the Company is not reflected in its current share price.

Given the strong language and management/board's 75% ownership block, seems like this is the best that minority shareholders can hope for here.  The accounting is extremely convoluted making it hard to value, insiders clearly have an advantage and this could be a take under.  But shares trade for $7.60/share, offering ~18% upside to the non-binding offer.  Management isn't really incentivized here to promote a stink bid (although, I don't like that the third party consortium isn't named), there is a share buyback plan in place, management hasn't been selling into it, why would they artificially raise the price?  Absent the stock trading a premium, seems like the natural course here would be for management to eventually squeeze out minority shareholders as Burkle suggests in his letter.

Unlike 23andMe, this is an actual business and not a science project, reasonable people can debate how much it is worth, but it doesn't have a shot clock on it in the same way.  Less upside, but it seems reasonable that the 75% ownership block finds a way to get this out of the press and public eye which can't be good for business.

Disclosure: I own shares of SHCO

23andMe Holding: Busted SPAC, CEO Wants Go-Private Transaction

I put out the call for reader ideas and as usual, received many good ones.  A couple intrigued me enough to start small positions, one of those is 23andMe Holding (ME) ($100MM market cap).  23andMe is a well known direct-to-consumer DNA kit company that went public in 2021 via a Richard Branson SPAC at a $3.5B valuation.  It came public with lofty expectations and a lot of hoopla, but it failed to create a sustainable business model beyond the one time novelty nature of getting your DNA sequenced.  The stock price has fallen 95+%.

23andMe was co-founded by Anne Wojcicki, she has an interesting backstory as a high profile Silicon Valley founder who enjoyed the spotlight when the company was a venture darling.  I imagine the fall has been challenging, her identity is tied to the company.  Back in April 2024, Wojcicki disclosed in an amendment to her 13D that she was exploring taking the company private:

On April 13, 2024, Ms. Wojcicki notified members of the special committee (the “Special Committee”) of the Board that she is considering making a proposal to acquire the Issuer in a potential go-private transaction. Ms. Wojcicki indicated that she was working with advisors and intended to begin speaking to potential partners and financing sources. Ms. Wojcicki stated that any proposal by her would be conditioned irrevocably upon the approval of the Special Committee and a majority of the unaffiliated stockholders of the Issuer. Ms. Wojcicki also indicated that she wishes to maintain control of the Issuer and, therefore, will not be willing to support any alternative transaction. There can be no assurance that the foregoing will result in any transaction or any other strategic alternative and or whether or when any of the foregoing may happen.

In July, she submitted her non-binding proposal for $8/share (split adjusted, the company did a 1-for-20 reverse split in October, trades for $3.75/share today).  The WSJ reported "directors wrote in a letter few days later they were disappointed because it offered no share-price premium and lacked committed financing.  The directors threatened to engage a consultant to find a sustainable business model if she didn't revise her offer quickly."  Then in September, the drama (its not often a $100MM market cap company gets repeated coverage in the WSJ) ratcheted it up further when the entire board (other than Wojcicki) resigned in unison:

Dear Anne,
We, the independent directors of the 23andMe Board, hereby tender our resignations, effective immediately.
After months of work, we have yet to receive from you a fully financed, fully diligenced, actionable proposal that is in the best interests of the non-affiliated shareholders. We believe the Special Committee and the Board have provided ample time for you to submit such a proposal. That we have not seen any notable progress over the last 5 months leads us to believe no such proposal is forthcoming. The Special Committee is therefore unwilling to consider further extensions, and the Board agrees with the Special Committee’s determination.
While we continue to wholeheartedly support the Company’s mission and believe deeply in the value of the personalized health and wellness offering that you have articulated, it is also clear that we differ on the strategic direction for the Company going forward. Because of that difference and because of your concentrated voting power, we believe that it is in the best interests of the Company’s shareholders that we resign from the Board rather than have a protracted and distracting difference of view with you as to the direction of the Company.
We are proud of what 23andMe has achieved in pioneering direct access to genetic information, and we have been honored to have had the opportunity to be part of those efforts.

 A few weeks later, Wojcicki amended her 13D again to include the below language:

In response to a request from the then-current Special Committee of the Board, I stated that I would consider third party takeover proposals for 23andMe. Whether I would ultimately accept such a proposal remained within my discretion. In the interim period, based on subsequent developments, it has become even clearer to me that the best path forward for the Issuer is for me to take the company private. Accordingly, in order to update my prior statement and avoid any confusion in the market, I am no longer open to considering third party takeover proposals for the Issuer. I remain committed to completing an acquisition of 23andMe. Towards that end, the Issuer is working diligently to repopulate the Board of Directors so that any proposals to acquire the Issuer can be properly considered.

Wojcicki likes to tout that she's unconventional, but this is very direct language and surprising to see in an SEC filing.  To help facilitate this potential go-private offer, three new independent board members were appointed at the end of October, none of which appear to own any shares.

In November, 23andMe shut down their drug discovery and development business (one business model they've tried out is that of a regular-way biotech, they had two clinical trials running) and laid off 40% of their workforce in order to meet their goal of getting to cash flow positive in their traditional consumer DNA kit business.  Progress is being made, but potentially not fast enough, in their 9/30 10-Q, the company had a going concern disclosure, they need to raise capital in order to fund operations for the next 12 months.  This is a time sensitive trade, although 23andMe doesn't have any conventional debt (they do have a fairly big fancy operating lease), they're running out of cash quickly.

The bet here is that Wojcicki is able to take the company private with the re-constituted board presumably picked as friendly.  Dealing with public shareholders and the bad press associated with a stock down so substantially is bad for the brand (both her and 23andMe).  I'm sympathetic to the view 23andMe might have some valuable data, brand (they own one of countless online pharmacies getting into compounded GLP-1s) and IP that might be valuable to someone, especially in the current artificial intelligence hype cycle.

Other thoughts/notes:

  • Anne Wojcicki rolled over all of her equity into the SPAC, contributed $25MM to the PIPE at $200 (split adjusted) per share and hasn't sold any of her shares since.  She appears to be a true believer in the company and its mission, although she's likely fabulously wealthy after previously being married to Google co-founder Sergey Brin for years.
  • She owns 22.8% of the stock and 49.9% of the vote due to the dual class share structure, Class A (the publicly traded class) has 1 vote and the Class B shares have 10 votes.  No other significant holders remain, Branson is long gone, etc. 

Disclosure: I own shares of ME